AbbVie (ABBV) Inventory Average (2013 - 2026)
AbbVie (ABBV) reported Inventory Average of $5.0 billion for Q1 2026, up 14.85% year-over-year from $4.4 billion in Q1 2025, and up 1.12% quarter-over-quarter from $4.9 billion in Q4 2025.
AbbVie (ABBV) Inventory Average (2013 - 2026) Analysis & Trends
AbbVie (ABBV) has 14 years of Inventory Average data on file, last reported at $5.0 billion in Q1 2026.
- Inventory Average for Q1 2026 came in at $5.0 billion, up 14.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 billion (up 14.85% YoY), and the FY2025 annual result was $4.6 billion, up 10.29% from the prior year.
- Inventory Average advanced to $5.0 billion in Q1 2026 per ABBV's latest filing, from $4.9 billion in the prior quarter.
- Over five years, Inventory Average peaked at $5.0 billion in Q1 2026 and troughed at $3.3 billion in Q3 2022.
- A 5-year average of $4.1 billion and a median of $4.2 billion in 2024 frame the typical range for Inventory Average.
- The sharpest annual moves came in 2022 and 2023: Inventory Average climbed 0.44% in 2022, then rose 22.35% in 2023.
- A 5-year view of Inventory Average shows it stood at $3.4 billion in 2022, then rose by 19.69% to $4.0 billion in 2023, then rose by 6.82% to $4.3 billion in 2024, then advanced by 14.58% to $4.9 billion in 2025, then increased by 1.12% to $5.0 billion in 2026.
- Business Quant data shows ABBV's Inventory Average at $5.0 billion in Q1 2026, $4.9 billion in Q4 2025, and $4.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 8.09 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 14.14 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 14.39 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 5.00 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 6.57 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 6.21 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.84 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 10.66 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.72 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.00 Bn |
| Dec 31, 2025 | 4.94 Bn |
| Sep 30, 2025 | 4.95 Bn |
| Jun 30, 2025 | 4.74 Bn |
| Mar 31, 2025 | 4.35 Bn |
| Dec 31, 2024 | 4.32 Bn |
| Sep 30, 2024 | 4.33 Bn |
| Jun 30, 2024 | 4.23 Bn |
| Mar 31, 2024 | 4.17 Bn |
| Dec 31, 2023 | 4.04 Bn |
| Sep 30, 2023 | 4.02 Bn |
| Jun 30, 2023 | 3.94 Bn |
| Mar 31, 2023 | 3.71 Bn |
| Dec 31, 2022 | 3.38 Bn |
| Sep 30, 2022 | 3.28 Bn |
| Jun 30, 2022 | 3.44 Bn |
| Mar 31, 2022 | 3.31 Bn |
| Dec 31, 2021 | 3.11 Bn |
| Sep 30, 2021 | 3.24 Bn |
| Jun 30, 2021 | 3.33 Bn |